Search results
Alumis cuts IPO size, but nets $250M for immune drug work
BioPharma Dive· 2 days agoAlumis’ public offering comes during an uptick in interest in immune drugs. Still, the company sold...
Indian Pharma exports: 'USD 10 bn opportunity up for grabs in off patent drug market by 2029' - ET...
The Economic Times· 2 days agoHyderabad: As many as 15 blockbuster drugs whose revenues worth USD 112 billion will be off-patented...
AI and stable funding environments are catalysts for biotech assets
Pharmaceutical Technology· 2 days agoAs revenue growth is what drives biopharma share prices, what these big companies need are...
2seventy bio completes $40m haemophilia A program deal with Novo Nordisk
Pharmaceutical Technology· 2 days agoAbecma gained approval from the US Food and Drug Administration (FDA) in April 2024. An FDA...
CAR T cells in lupus: Promising results at EULAR 2024 and emergence of China
Clinical Trials Arena· 2 days ago...Investigational New Drug cleared (US) China BCMA-CD19 cCAR T cells iCell Gene Therapeutics LLC...
2seventy slims down with sale of hemophilia assets to Novo
BioPharma Dive· 2 days agoLast September, longtime Bluebird CEO Nick...to Regeneron Pharmaceuticals for cheap in a deal that...
Capturing the genAI boom for drug development
Pharmaceutical Technology· 3 days agoOne of the biggest deals in recent times involved Bristol Myers Squibb (BMS), who tied down the services of US deep tech company VantAI ...
ASCO24: Novartis’ Scemblix outperforms standard of care in CML
Pharmaceutical Technology· 4 days ago“When you combine superior response with the excellent safety and tolerability profile...
ASCO24: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC
Pharmaceutical Technology· 4 days agoFollowing the positive results, the company now plans to start a global Phase III clinical trial...
BMS expands Krazati’s FDA label to include colorectal cancer
Clinical Trials Arena· 4 days agoKrazati pulled in $21m in sales in the first quarter of this year, per BMS financials. It is...